🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07779421
Recruiting Not applicable

THBC/CGF for Alveolar Bone Regeneration: A Real-World Study

NCT07779421 · tracked via the Priya Life Science China tracker
Sponsor
Stomatological Hospital Affiliated with Fujian Medical University
Phase
Not applicable
Started
2024-08-01
Last updated
2026-08-21

Condition(s) studied

Alveolar Bone LossAlveolar Ridge Resorption After ExtractionTooth, Impacted

Investigational drug(s) / intervention(s)

Temperature-sensitive hydroxybutyl chitosan-loaded concentrated growth factorTemperature-sensitive hydroxybutyl chitosanAutologous Concentrated Growth FactorNatural Healing without Biomaterial Intervention

Temperature-sensitive hydroxybutyl chitosan-loaded concentrated growth factor: * THBC Component: Its key component is hydroxybutyl chitosan. The product is supplied as a clear or light yellow, easily flowing liquid at storage temperature (2-8 degrees Celsius) and undergoes a sol-gel transition to form a transparent or semi-transparent gel at body temperature (37 +/- 2 degrees Celsius). The product is composed of hydroxybutyl chitosan, glycerol, and purified water. It is designed to provide a physical barrier, create a moist wound-healing environment, and alleviate pain. * CGF Component: Concentrated Growth Factor (CGF) is a third-generation autologous platelet concentrate obtained from the patient's own venous blood through a specific centrifugation process. It presents as a dense, three-dimensional fibrin matrix rich in platelets, leukocytes, cytokines, and growth factors (such as PDGF, TGF-beta, VEGF). * Composite Process: Mixed under sterile conditions, injection flow rate less than or equal to 0.5 mL/s.

Temperature-sensitive hydroxybutyl chitosan: Its key component is hydroxybutyl chitosan. The product is supplied as a clear or light yellow, easily flowing liquid at storage temperature (2-8 degrees Celsius) and undergoes a sol-gel transition to form a transparent or semi-transparent gel at body temperature (37 +/- 2 degrees Celsius). The product is composed of hydroxybutyl chitosan, glycerol, and purified water. It is designed to provide a physical barrier, create a moist wound-healing environment, and alleviate pain.

Autologous Concentrated Growth Factor: Concentrated Growth Factor (CGF) is a third-generation autologous platelet concentrate obtained from the patient's own venous blood through a specific centrifugation process. It presents as a dense, three-dimensional fibrin matrix rich in platelets, leukocytes, cytokines, and growth factors (such as PDGF, TGF-beta, VEGF).

Natural Healing without Biomaterial Intervention: After tooth extraction, gently scraping the bone wall induces bleeding, allowing a natural blood clot to form. Within 30 minutes postoperatively, ensure the clot fills more than 90 percent of the socket without applying experimental biomaterials.

Study summary

This study aims to combine real-world research with relevant bone repair materials and techniques to improve alveolar bone resorption in extraction sockets following impacted wisdom tooth removal, while achieving effective bone preservation or promoting bone regeneration. All eligible cases within specified parameters will be included in the clinical study scope. Based on real-world clinical data, we will proactively collect postoperative clinical examination findings and imaging data. Statistical analysis will be performed on clinical outcomes and follow-up data from patients undergoing mandibular impacted M3 extraction. The study aims to clarify the therapeutic efficacy of the thermosensitive hydroxyethylchitosan-loaded concentrated growth factor group in repairing mesial bone defects of M2s following M3 extraction.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
* Inclusion Criteria: * Preoperative CBCT imaging confirming mandibular third molars (M3s) with low to moderate impaction according to the Pell and Gregory classification, and not in the acute inflammatory stage. * Ipsilateral mandibular second molars (M2s) with retention value and no indication for extraction. * Patients able to provide written informed consent and willing to comply with the scheduled follow-up visits. * Age between 18 and 60 years (inclusive). * Exclusion Criteria: * Presence of systemic diseases or other contraindications to tooth extraction surgery. * Known or suspected current malignancy. * History of radiation therapy to the head and neck region. * History of chemotherapy within 5 years prior to surgery. * Smoking \> 15 cigarettes per day. * Subjects with mental or neurological disorders, or otherwise unable to provide informed consent.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Stomatological Hospital Affiliated with Fujian Medical University Fuzhou Fujian Recruiting

More Stomatological Hospital Affiliated with Fujian Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07779421 on ClinicalTrials.gov ↗ ← All trials in China